Group items tagged

The MedEdge Life Sciences Business Summit will be taking place on June 14th, 2012 at the Richmond Hill Centre for the Performing Arts which will take a look at how to enter the healthcare market and understand the procurement process. Dr Usha Srinivasan, Program Director, Business Acceleration Program (BAP), MaRS Discovery District will be speaking at the event.

CHALLENGE: It's got potential and is ready to be built, but is the science sound? And can a fringe medical treatment have mass appeal?

Lew Lim founder of Mediclights is a MaRS client and is bringing intranasal light therapy to Canada. Peter Adams, a MaRS Life Science and Healthcare IT advisor is working with Lim to commercializing this innovation. They would like to see Toronto as the new hub for interanasal laser research.

LidiasWorld blogs about the Entrepreneurship 101 class she and her partner attended at MaRS with guest speaker Dr. Stuart Foster, the founder of VisualSonics, spoke mainly about the challenges of being a science tech specific startup.

In 2009, the Chinese central government spent $18.75 billion on healthcare up 50 percent year over year. For 2010, spending is forecast at $20.36 billion, which would be an 8.8 percent increase year over year

With Healthcare legislation well on its way to ultimate approval and implementation, the winds are now calming and its becoming clearer what the tornado has left behind for the pharmaceutical industry. Many had feared it would result in permanent widespread damage, but it appears the storm may actually have carved a path toward greener pastures for the industry.

Outlines Event schedule for Toronto Innovation Forum June 16, 2009 Program "Opportunity, Creativity and Partnership"

Outlines Event schedule for Toronto Innovation Forum June 16, 2009 Program "Opportunity, Creativity and Partnership." Veronika Litinski, Practice Lead, Healthcare and Life Sciences, MaRS will talk about Best Practices in Venture Creation.

"MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek, Beijing/China) have announced a strategic partnership to co-develop a therapeutic cream aimed at reducing scar formation post surgery."

According to Theresa Boyle, Health Report of The Star, states that scientists have discovered the process that underlies in the development of cancer cell mutations in breast cancer. Mike Stratton who is part of the International Cancer Genome Consortium at the MaRS Centre states these "findings will go a long way in helping the consortium achieve its goal of mapping the genetic mutations in 50 different types of cancer by 2018."

Canadian Researchers from Princess Margaret Cancer Program found a potential new leukemia treatment with an old antibiotic drug. MaRS Innovation partly assisting funding the research.

Segasist Technologies, a MaRS Discovery District Client, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Prostate Auto-Contouring software 'Segasist P-AC'.

"Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."

MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

Robert Lawton Burns focuses on the key role of the 'producers' as the main source of innovation in this wide-ranging analysis of business trends in the manufacturing branch of the health care industry. Written by industry academics and executives, the book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. Most importantly, it describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others.

MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries. Dec 15, 2009

Jim Perlot, CFO, Arctic Group, who has developed a DNA test, Macular Risk, that identifies people who are at risk of developing this eye disease is interviewed by BNN. Oct 23, 2009

Genome Alberta's Mike Spear was at the MaRS Centre symposium on synthetic biology. Oct 28, 2009

Synthetic Biology is a new approach to engineering biology, with an emphasis on technologies to write DNA. Mike Spear shares his views after attending the event on Engineering the Future: Synthetic Biology. Oct 27, 2009

Segasist Technology has developed special software for doctors to help read medical images. Jaqueline Csonka-Peeren, president and CEO, Segasist Technology tells BNN more. Nov 6, 2009